SPDR S&P Biotech ETF (XBI) Short Interest Ratio & Short Volume

Short interest is the volume of SPDR S&P Biotech ETF shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 79,500,000 shares of XBI short. 146.01% of SPDR S&P Biotech ETF's shares are currently sold short. Learn More on SPDR S&P Biotech ETF's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XBI shares currently have a short interest ratio of 8.0. Learn More on SPDR S&P Biotech ETF's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of SPDR S&P Biotech ETF: Marex Group plc, Hudson Bay Capital Management LP, Wolverine Trading LLC, Nomura Holdings Inc., Soleus Capital Management L.P., Rubric Capital Management LP, Perceptive Advisors LLC, Hudson Bay Capital Management LP, BNP Paribas Financial Markets, Boothbay Fund Management LLC, Bank of America Corp DE, Nantahala Capital Management LLC, Jane Street Group LLC, Camber Capital Management LP, Parkwood LLC, Caption Management LLC, Squarepoint Ops LLC, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC , Affinity Asset Advisors LLC, Walleye Capital LLC, Walleye Trading LLC, NINE MASTS CAPITAL Ltd, Hsbc Holdings PLC, Capital Fund Management S.A., Jefferies Financial Group Inc., Eisler Capital Management Ltd., Citigroup Inc., Credit Industriel ET Commercial, FNY Investment Advisers LLC, Twin Tree Management LP, Credit Industriel ET Commercial, and Quaker Wealth Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 146.01% of SPDR S&P Biotech ETF's floating shares are currently sold short.

SPDR S&P Biotech ETF saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 79,500,000 shares, an increase of 14.3% from the previous total of 69,580,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

146.01% of SPDR S&P Biotech ETF's shares are currently sold short. Here is how the short interest of companies compare to SPDR S&P Biotech ETF: iShares Biotechnology ETF (29.39%), iShares U.S. Medical Devices ETF (2.84%), iShares Global Healthcare ETF (0.20%), iShares U.S. Healthcare ETF (1.30%), Fidelity MSCI Health Care Index ETF (0.04%), First Trust NYSE Arca Biotechnology Index Fund (0.09%), First Trust Health Care AlphaDEX Fund (0.00%), iShares U.S. Healthcare Providers ETF (2.28%), Invesco S&P 500 Equal Weight Health Care ETF (1.55%), Direxion Daily S&P Biotech Bull 3x Shares (15.38%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling XBI is an investing strategy that aims to generate trading profit from SPDR S&P Biotech ETF as its price is falling. XBI shares are trading up $0.36 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for SPDR S&P Biotech ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XBI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XBI, twice per month. The most recent reporting period available is July, 31 2025.